The recombinant anti-MET/EpCAM bispecific antibody fragment: a promising novel therapeutic approach for breast cancer treatment
Investigational New Drugs · 2025
DOI: 10.1007/s10637-025-01546-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Investigational New Drugs, 2025. Verfasst von Roya Mirzaei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Epithelial Cell Adhesion Molecule, Antibodies, Bispecific, Proto-Oncogene Proteins c-met, Triple Negative Breast Neoplasms. Die Arbeit nennt 65 Literaturangaben.
Abstract (Originalsprache)
Our study aims to target Met and EpCAM to inhibit angiogenesis in breast cancer, particularly triple-negative breast cancer (TNBC). We have developed a new bispecific antibody that targets both MET and EpCAM, which are commonly overexpressed in tumor cells. This antibody aims to reduce tumor cell proliferation and spread. After cloning and expressing the anti-Met/EPCAM sequence in Escherichia coli, we confirmed its accuracy through Western blot analysis. Flow cytometry indicated its binding activities to MET and EPCAM on MDA-MB-231 and MCF-7 cell lines. Our antibody showed anti-proliferative potential as indicated by apoptosis and MTT assay, leading to the inhibition of migration and invasion in breast cancer cell lines. After conducting a thorough analysis of cytokine production, we discovered that our bispecific antibody effectively influenced the levels of IL-8 and IL-6. These cytokines play crucial roles in angiogenesis and the progression of breast cancer. These findings indicate that our bispecific antibody holds promise as a potential therapy for triple-negative breast cancer. It has the potential to impede the formation of new blood vessels in tumors, thus restraining their growth and spread.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
- Department of Biochemistry, Medical Faculty, Saveh Branch, Islamic Azad University, Saveh, Iran.
- Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Department of Anesthesiology, Pain, and Critical care, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Molecular and Translational Medicine, Nocivelli Institute for Molecular Medicine, University of Brescia, Brescia, Italy.
Zitieren
APA
Mirzaei, R., Azimi, M., Karimi, S., Karimi, M. S., Aghel, S. A. M., Salehi, M., Jalili, N., Yadegari, F., & Farahmand, L. (2025). The recombinant anti-MET/EpCAM bispecific antibody fragment: a promising novel therapeutic approach for breast cancer treatment. Investigational New Drugs. https://doi.org/10.1007/s10637-025-01546-3
Vancouver
Mirzaei R, Azimi M, Karimi S, Karimi MS, Aghel SAM, Salehi M, et al. The recombinant anti-MET/EpCAM bispecific antibody fragment: a promising novel therapeutic approach for breast cancer treatment. Investigational New Drugs. 2025. doi:10.1007/s10637-025-01546-3
BibTeX
@article{Mirzaei2025,
author = {Mirzaei, Roya and Azimi, Mohammadreza and Karimi, Soroush and Karimi, Mahshid Seyed and Aghel, Seyed Ali Mir and Salehi, Malihe and Jalili, Neda and Yadegari, Fatemeh and Farahmand, Leila},
title = {The recombinant anti-MET/EpCAM bispecific antibody fragment: a promising novel therapeutic approach for breast cancer treatment},
journal = {Investigational New Drugs},
year = {2025},
doi = {10.1007/s10637-025-01546-3}
}
EUVIMED